<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60337">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02320474</url>
  </required_header>
  <id_info>
    <org_study_id>ATTRACT</org_study_id>
    <nct_id>NCT02320474</nct_id>
  </id_info>
  <brief_title>Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)</brief_title>
  <acronym>ATTRACT</acronym>
  <official_title>Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a one-year pilot, interventional, prospective, single arm, non-randomized,
      multicentric (3 centers) controlled study that aims to evaluate the response of type 3
      choroidal neovascularization to treatment by Aflibercept following a classic protocol.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>52 weeks</time_frame>
    <description>Mean change from baseline in Best Corrected Visual Acuity (BCVA) as measured by ETDRS letter score at 4 meters</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Type 3 Choroidal Neovascularization</condition>
  <arm_group>
    <arm_group_label>Aflibercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <arm_group_label>Aflibercept</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females aged more than 50 years

          -  Patients with type 3 choroidal neovascularization assessed on FA, ICG and OCT

          -  Exudation on SD-OCT scans defined by intraretinal cysts or subretinal fluid.

          -  Best Corrected Visual Acuity at inclusion between 24 and 78 letters (ETDRS)

          -  Media clarity, pupillary dilation and patient cooperation sufficient to allow fundus
             photographs of adequate quality

        Exclusion Criteria:

          -  Any contraindications as reported in the labelling of Aflibercept (Eylea®): Ocular or
             periocular infection, Active intraocular inflammation or Hypersensitivity.

          -  Any previous history of intravitreal injections in the study eye for exudative AMD

          -  Any secondary chorioretinal anastomosis due to retinal scar or fibrosis

          -  Any history of vitrectomy

          -  Media opacities preventing accurate imaging of the retina (cataract)

          -  Any other retinal disorder possibly associated with type 3 CNV (epiretinal membrane,
             macular hole)

          -  Confirmed intraocular pressure ≥25 mmHg or non-stable glaucoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas LEVEZIEL, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU POITIERS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas LEVEZIEL, MD, PhD</last_name>
    <phone>+33 (0)5.49.44.41.82</phone>
    <email>nicolas.leveziel@chu-poitiers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Poitiers University Hospital</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas LEVEZIEL, MD,PhD</last_name>
      <phone>+33 (0)5.49.44.41.82</phone>
      <email>nicolas.leveziel@chu-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinic of POITIERS</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hélène TOURE-MANIC, MD</last_name>
      <phone>+33 (0)5.49.46.14.80</phone>
      <email>manic_h@yahoo.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 10, 2016</lastchanged_date>
  <firstreceived_date>December 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
